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Abstract
Oral streptococci are a heterogeneous group of human commensals, with a potential to cause serious infections. Activation
of plasminogen has been shown to increase the virulence of typical human pathogenic streptococci such as S. pneumoniae.
One important factor for plasminogen activation is the streptococcal a-enolase. Here we report that plasminogen activation
is also common in oral streptococci species involved in clinical infection and that it depends on the action of human
plasminogen activators. The ability to activate plasminogen did not require full conservation of the internal plasminogen
binding sequence motif FYDKERKVY of a-enolase that was previously described as crucial for increased plasminogen
binding, activation and virulence. Instead, experiments with recombinant a-enolase variants indicate that the naturally
occurring variations do not impair plasminogen binding. In spite of these variations in the internal plasminogen binding
motif oral streptococci showed similar activation of plasminogen. We conclude that the pathomechanism of plasminogen
activation is conserved in oral streptococci that cause infections in human. This may contribute to their opportunistic
pathogenic character that is unfurled in certain niches.
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Introduction
Oral streptococci are commensal microorganisms that may
exert beneficial probiotic effects when residing at their natural
habitat, the oral cavity. However, when they gain access to deeper
oral tissues, the microorganisms invoke pathogenic processes in
order to ensure their own survival, thereby becoming a substantial
threat to the host with whom they normally live in symbiosis. Oral
streptococci of the anginosus- and the mitis group are frequently
found in human infections. The anginosus group (Streptococcus
anginosus, S. constellatus, S. intermedius) is associated with bacteremia,
purulent infections and severe abscess formation in the deep neck
and in inner organs [1,2,3,4], with S. constellatus also implicated in
the pathogenesis of periodontitis [5]. Systemic infections with oral
streptococci, in particular with members of the mitis group (S.
mitis, S. oralis, S. gordonii, S. sanguinis, S. parasanguinis), are a very
frequent cause for infective endocarditis [6,7]. Despite consider-
able pathogenic potential of the causative organisms and the
clinical relevance of infections with oral streptococci, their
molecular pathogenesis is barely understood. Some of their
pathogenic actions may be unique to oral streptococci, while
others may show high similarity to those of the more extensively
studied streptococci. The latter very often use the host plasmin-
ogen system in order to invade tissues and establish an infection.
The physiological role of the plasminogen system is the
degradation of fibrin clots during wound healing. In non-infected
tissue the zymogen (plasminogen) is proteolytically activated to
plasmin by tissue type plasminogen activator or urokinase. The
activated enzyme plasmin is a broad-spectrum serine protease
which degrades not only fibrin, but also extracellular matrix
proteins such as fibronectin, laminin and proteoglycans. The
protease inhibitors a2-antiplasmin and a2-macroglobulin tightly
control the activity of plasmin [8]. Bacteria exploit the proteolytic
activity of the plasminogen system to overcome physical barriers
formed by the host’s extracellular matrix and the coagulation
system when invading host tissue; a prerequisite for successful
infection and bacterial dissemination (reviewed in [8]). Strepto-
cocci have developed a variety of factors and mechanisms for
surface capture and activation of plasmin(ogen). Some streptococci
exploit the host’s plasminogen activators [9,10,11]. S. pyogenes and
species that belong to the Lancefield groups C and G express their
own potent plasminogen activator, streptokinase, which changes
the conformation of the unprocessed catalytic domain of
plasminogen into a proteolytically active form [8]. In addition,
binding to streptococcal plasminogen receptors may prevent the
action of host inhibitors as seen for a2-antiplasmin and the broad
spectrum protease inhibitor a2-macroglobulin [12,13]. M-like
proteins such as PAM, Prp, MLC36 and MLG72 confer the ability
to bind high quantities of plasmin(ogen) to S. pyogenes [9,14] or
group C and G streptococci [15], thereby increasing their
virulence [16]. Interestingly strains of S. pyogenes and S. pneumoniae
that do not possess specialized plasminogen receptors make use of
their own metabolic enzymes to recruit plasmin(ogen). Glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) and a-enolase,
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receptors on the surface of both S. pyogenes [17,18,19] and S.
pneumoniae [20,21]. The a-enolase of S. pneumoniae has been
implicated in plasmin-dependent penetration of biological mem-
branes during invasive infections [22]. The efficiency of plasmin-
ogen activation by a-enolase and the resulting invasiveness
depends not only on two lysine residues in the C-terminal end
of the streptococcal protein [23], but is also mediated by an
internal binding motif: FYDKERKVY [22,24]. Recent investiga-
tions on the a-enolase of S. mutans [25] suggest that variations of
this internal binding motif exist (FYDNG—VY), which may
impair efficient plasminogen binding and activation. Here we
describe the natural variations that occur within the internal
plasminogen binding motif of streptococcal a-enolase from
different species. Moreover, we have comprehensively investigated
the influence of natural variations on plasminogen binding and
overall activation of plasminogen by oral streptococci.
Results
Binding of plasminogen to Streptococcus oralis
Streptococci are known to interact with various plasma proteins.
Such multiple interactions may influence one another by masking
or competing for binding sites and by providing new binding sites
for secondary interactions. Therefore, the interactions of the
clinical S. oralis isolate SV11 with human plasma proteins were
investigated by incubating the bacteria with human plasma or PBS
as a control. Bound proteins were eluted from the surface of the
bacteria, separated by SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) (Fig. 1), and identified by either MALDI-TOF-MS
or by immunoblot analysis (data not shown). This experiment
identified three major ligands bound by S. oralis isolate SV11:
serum albumin, IgG, and plasminogen. An analogous experiment,
in which S. oralis isolate SV11 was incubated with a solution of
purified human plasminogen demonstrated its direct interaction
with the bacterial surface indicating that the binding does not
depend on other factors from human plasma (Fig. 1).
Surface localization of a-enolase on S. oralis
Examination of alkaline eluates of streptococcal surface
molecules by immuno blot with anti-sera specific for a-enolase
and GAPDH (Fig. 2) indicated the presence of two proteins of S.
oralis SV11 that are known plasminogen binding factors in other
streptococcal species [17,18,20,21]. Specificity of this experiment
was supported by the observation that the mobility of the proteins
in SDS-PAGE, which corresponded to molecular masses of 51 and
53 kDa, respectively, was in agreement with the calculated
molecular masses of streptococcal a-enolase (47 kDa, GenBank
accession no.: ZP_06612198) and GAPDH (36 kDa to 50 kDa;
GenBank accession no.: BAD02480 and ZP_06612207). The
experiment demonstrated the presence of two non-covalently
bound plasminogen binding factors on the surface of S. oralis
SV11. It remained to be tested if plasmin(ogen) binding to the
surface of the bacteria were concomitant with activation of the
protease.
Plasminogen activation by S. oralis
In human plasma, plasminogen activation is tightly controlled
by potent inhibitors, a2-antiplasmin and a2-macroglobulin. To test
the ability of S. oralis to generate plasmin activity against the action
of the inhibitors, experiments with a plasmin(ogen) specific
substrate (S-2251) were conducted (Fig. 3A). Controls demon-
strated that human plasma or the SV11 strain in PBS, possessed
low or no intrinsic activity against the S-2251 substrate,
respectively. Incubation of human plasma with S. oralis SV11, as
compared to the controls, led to a strongly increased conversion of
the substrate after 90 min that continued for up to 6.5 h, which
demonstrated that S. oralis SV11 can activate plasminogen against
the actions of its inhibitors in human plasma (Fig. 3A). In
additional experiments, S. oralis SV11 when incubated with
purified plasminogen in PBS failed to cause substrate conversion,
indicating a lack of a streptococcal plasminogen activator and thus
activation by host factors from plasma (Fig. 3B).
Variations in the internal plasmin(ogen) binding motif of
a-enolase in clinical isolates of oral streptococci
Previous work on S. pneumoniae a-enolase revealed that
plasmin(ogen) binding is mediated not only by two C-terminal
lysine residues, but also by an internal plasmin(ogen) binding motif
(IPM) with the sequence FYDKERKVY, which has a crucial
influence on the efficiency of plasmin(ogen) binding and
utilization. The distribution, conservation and species specificity
of the IPM within the streptococci had not been comprehensively
studied. Consequently, the knowledge about its general role in
streptococcal pathogenesis remained insufficient. Sequencing of
the enolase gene (eno) revealed that strain S. oralis SV11 had an a-
enolase with an intact FYDKERKVY-motif. To gain insight into
the distribution and conservation of the motif among the oral
streptococci, a collection of 56 clinical isolates was subjected to
Figure 1. Binding of human plasma proteins to Streptococcus
oralis. After incubation of Streptococcus oralis SV11 with human blood
plasma (1), PBS containing purified human plasminogen (2), or PBS
alone (3) proteins that were bound to the bacterial surface were eluted
with glycine buffer (pH 2) and separated by 12% SDS-PAGE under
reducing conditions. The proteins were stained with Coomassie Brilliant
Blue. Mobility of marker proteins is indicated at the left and their
molecular mass is given in kDa. Protein bands that were identified as
plasminogen (Plg), human serum albumin (HSA), and immunoglobulin
G( IgG) are marked. The control experiment (3) indicates proteins of
bacterial origin.
doi:10.1371/journal.pone.0013826.g001
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comprised the species S. mitis, S. oralis, S. gordonii, S. sanguis and S.
parasanguis, which are members of the mitis group and genetically
closely related to S. pneumoniae. Moreover, the collection consisted
of strains from the anginosus group (S. anginosus, S. constellatus, S.
intermedius) and isolates of S. salivarius. An intact FYDKERKVY
motif was present in 46 of the 56 strains and was found in all of the
examined species. Of the nine S. salivarius isolates examined six
strains had an IPM-like motif FYDAERKVY which was also
found in the majority of S. agalactiae (group B streptococci; i.e.
GenBank accession numbers: ABA45999.1, AAM99524.1,
CAD46252.1) and S. thermophilus (i.e. GenBank accession numbers:
ABJ65942.1, AAV62231.1, AAV60341.1) strains. In S. salivarius
SV32 the FYDKERKVY-motif was conserved, while two strains
(S. salivarius SV17 and SV107) possessed an a-enolase with a
variant FYENG—VY-motif, which resembles the IPM-like
sequences in the cariogenic streptococci S. mutans (FYDNG—
VY) and S. sobrinus (FYEDG—VY). In all but two of the strains
that belong to the mitis group the prototypical IPM of S. pneumoniae
was conserved. In one of the six S. mitis and one of the seven S.
oralis isolates the a-enolase contained a FYDKERQVY-motif.
Interestingly the IPM of S. pneumoniae was also present in the less
related (based on comparison of 16S-rRNA gene sequence [26])
streptococci of the anginosus group. The previously described C-
terminal plasminogen binding motif, which is formed by two
terminal lysine residues (KK) [23,24,27], was conserved in 34 of
the 56 isolates, this excludes all 19 anginosus group strains and a S.
salivarius strain (SV121) which all possessed a terminal SK instead.
In all the strains with the SK variant the FYDKERKVY sequence
of the IPM was conserved. In summary, the comparison of the
IPM(-like) amino acid sequences revealed a lack of species
specificity. Moreover, a high prevalence of the FYDKERKVY
sequence in clinical isolates of different and distantly related oral
streptococci suggested that a conserved IPM may be of advantage
for streptococci.
Plasminogen binding of streptococcal a-enolases with
IPM variants
The variations in the IPM may influence the interaction
between plasmin(ogen) and a-enolase. Therefore, five different a-
enolases that represent all the sequence variations in the internal
plasminogen binding motif encountered in the collection of oral
streptococci were recombinantly expressed and isolated (Fig. 4).
All recombinant proteins carried the two C-terminal lysine
residues that are known to contribute to the interaction with
plasminogen [24,27] (Fig. 4). Binding experiments using dot-blots
and surface plasmon resonance measurements delivered consistent
results. All variants of the a-enolase interacted with radiolabeled
human plasminogen in dot blots, generating signals of similar
intensity which were comparable to a-enolase with the originally
described IPM (Fig. 5). Concentration dependent binding of all a-
enolase variants to immobilized human plasminogen was observed
in surface plasmon resonance measurements, with similar
apparent dissociations constants, ranging from 1.6 mMt o
0.2 mM (Fig. 5). Conclusively, naturally occurring variations in
the IPM, as encountered in oral streptococci, did not impair
plasminogen binding.
Figure 2. Bacterial a-enolase and GAPDH in bacterial surface
eluates of Streptococcus oralis. Surface bound proteins of S. oralis
SV11 were eluted with sodium carbonate buffer (pH 10), separated by
12% SDS-PAGE under reducing conditions and analysed by immunoblot
with rabbit antisera specific for a-enolase (1) or GAPDH (2), respectively.
Mobility of marker proteins is indicated at the left and their molecular
mass is given in kDa.
doi:10.1371/journal.pone.0013826.g002
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species of oral streptococci
Differences in plasminogen activation by streptococci may
crucially influence the pathogenesis of infection. Therefore, the
overall plasminogen activation in human plasma by oral
streptococci with different naturally occurring variants of the
IPM was compared (Fig. 6). All of the streptococcal isolates led to
an increased substrate conversion reflecting increased plasminogen
activation as compared to a negative control without bacteria.
Considerable differences in the activation were observed between
different strains although without clear correlation with the IPM
sequence or other mutations in the protein sequence. Only the two
S. salivarius strains SV17 and SV107 that contain a FYENG—VY-
motif showed a notably faster activation of plasminogen as
compared to the other strains. Instead, functional conservation
between different variants of the IPM, as demonstrated in the
experiments described above, suggests that this effect depends
either on quantitative differences in surface bound a-enolase or on
other streptococcal factors that activate plasminogen. In all tested
strains the C-terminal 70 amino acids of a-enolase were identical
and terminated with two lysine residues (GenBank accession
numbers: HQ398283, HQ398286, HQ398289, HQ398290,
HQ398309, HQ398310, HQ398313, HQ398314). Thus, diversity
in the C-terminal plasminogen binding motif was not responsible
for the observed differences in plasminogen activation. Taken
together, our experiments have demonstrated a similar capability
of different oral streptococci species that can cause disease in
humans to activate plasminogen independent of the naturally
occurring variations in the previously reported IPM with the
sequence FYDKERKVY [22].
Discussion
Degradation of host proteins by generation of plasmin-activity is
considered beneficial for streptococcal survival and dissemination
of infection by providing bacterial nutrition and increasing
bacterial mobility in the infected tissue [8,22,28,29]. The
experiments with S. oralis demonstrated that binding of plasmin-
ogen to the oral streptococci leads to its activation in a process that
fully depends on plasminogen activators of the host, contrary to S.
pyogenes and some of the Group C and G streptococcal species,
which express their own bacterial plasminogen activator strepto-
kinase [30,31]. This is consistent with the fact that homologues of
streptokinase genes were not found in the whole genome
sequences that were publicly available for oral streptococci and
several S. pneumoniae strains http://www.ncbi.nlm.nih.gov/
genomes/MICROBES/microbial_taxtree.html.
Previous work on S. pyogenes and S. pneumoniae has demonstrated
that the streptococcal intracellular metabolic enzymes, a-enolase
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), are
actively involved in binding to plasminogen triggering its
activation by the plasminogen activators of the host
[17,18,20,21,23,24]. The importance of the internal plasminogen
binding motif of a-enolase (IPM) for this virulence related function
on the surface of S. pneumoniae has been demonstrated unequiv-
ocally in experiments with synthetic peptides, recombinant protein
variants and mutated bacterial strains [22,24]. Mutations in the
lysine residues and the glutamic acid residue of the FYD-
KERKVY motif abolish plasminogen binding [24], thereby
drastically diminishing the a-enolase driven activation of plasmin-
ogen by host plasminogen activators [22] and the recruitment of
plasmin(ogen) to the bacterial surface [24]. As a consequence
degradation of extracellular matrix and fibrin clots by the S.
pneumoniae mutant is impaired [22]. The significant role of the IPM
Figure 3. Plasminogen activation by Streptococcus oralis. (A)
Bacterial cells from mid-logarithmic culture of S. oralis SV11 were
incubated in human plasma (#) or PBS (e). Plasma without bacteria
was used as a control for auto-activation (%). Incubation of plasma with
100 ng urokinase served as a positive control (n) (B) Bacterial cells from
mid-logarithmic culture of Streptococcus oralis SV11 were incubated in
PBS (e) or PBS containing purified human plasminogen (#).
Plasminogen without bacterial cells (%) served as a control for auto-
activation. Incubation of human plasminogen with 100 ng urokinase
served as a positive control (n), demonstrating that the plasminogen
could be activated. Plasminogen activation was measured using the
colour reaction of plasmin-specific substrate (S-2251). The diagrams
depict the absorbance of the liquid phase measured at a wavelength of
405 nm vs. time.
doi:10.1371/journal.pone.0013826.g003
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virulence of the mutant strain in intranasally infected mice [24].
S. pneumoniae is genetically closely related to the oral streptococci of
the mitis group. Interestingly, cross species comparison of
streptococcal a-enolase revealed that the FYDKERKVY motif
of S. pneumoniae is not only conserved in the clinically important
human pathogen S. pyogenes, but also in the oral streptococci
species, which are considered as limited in their propensity to
cause disease. As shown in this study (Table 1), the FYDKERKVY
motif is conserved in the a-enolases of the anginosus group (19
isolates) and mitis group (26 isolates) streptococci with two
exceptions, one S. oralis (SV18) and one S. mitis isolate (SV28).
The majority of S. salivarius strains (8 out of 9) possess variants of
the IPM. According to experiments with isolated recombinant a-
enolases none of the naturally occurring variations in the IPM
impaired plasminogen binding, a reduction in which may diminish
their ability to drive plasminogen activation by the responsible host
factors.
The mode of the investigated interaction is not fully understood.
Plasmin(ogen) is equipped with lysine binding kringle domains and
its interaction with a-enolase is inhibitable by the lysine analog e-
aminocaproic acid (EACA) [22,23,32]. This suggested that lysine
residues of the a-enolase form contacts with plasminogen kringle
domains, which is in agreement with previous work that identified
the C-terminal two lysines of S. pyogenes and S. pneumoniae a-enolase
as a plasminogen binding motif [23,24,27]. Successive deletion of
the two terminal amino acids led to a gradual decrease in
plasminogen affinity, indicating that a single terminal lysine is
sufficient to strengthen the interaction [23]. However, replacement
of the terminal KK by KL or by LL led to a similar reduction in
plasminogen affinity in both mutated proteins [23,24]. This
suggested that the terminal of the two lysine residues had a more
important role in the interaction between a-enolase and
plasminogen. Notably, the KL and the LL variant showed a
lower affinity than the KK deletion mutant [23,24,27]. Thus, in
addition to a potential role as a contact site for plasminogen, the
terminal lysine appears to exert a stabilizing function on the a-
enolase structure that is important for binding of plasminogen via
the IPM. In our study the terminal KK motif was conserved in
64% of the oral streptococcal isolates. The remaining 36%, all
anginosus group strains and one S. sanguinis strain, terminated with
SK. Based on the data described above, one could speculate that
the penultimate position could tolerate such substitution of the
lysine residue without strong detrimental effect on plasminogen
binding. However, the interaction between plasminogen and a-
enolases with the C-terminal SK plasminogen remains to be
studied. In contrast to several other lysine substitutions in the a-
enolase [23,27], substitution of K
344 by glutamic acid had a
destabilizing effect on the ternary structure of S. pyogenes a-enolase,
which increased plasminogen binding but abolished phosphopy-
ruvate hydratase activity [27]. As expected for a-enolases of viable
bacteria, the analogous residue was conserved in all the examined
strains of our study.
Amino acid substitutions in the IPM of a-enolase that targeted
its lysine residues abolished plasminogen binding (FYDLGRLVY
[22,24]; FYDAERAVY [27]). Alanine substitution of both lysine
residues of the IPM induced limited structural changes that did not
affect the ternary structure of the protein or its enzymatic activity
[27]. In light of the inhibitory effect of EACA on the interaction
[22,23,32], it seemed conceivable that the lysine residues of the
IPM were directly involved in plasminogen binding, by forming
contact with lysine binding sites in the host protease. However, it
cannot be excluded that conformational changes in plasminogen
upon EACA binding may be the reason for the inhibition rather
than a competition for the lysine binding site [33,34,35,36], since
they could affect a possible lysine-independent binding motif of the
protein. Our comparison of a-enolase variants from different
viable streptococcal strains demonstrated a retained plasminogen
binding activity in spite of deviations from the previously described
IPM, which comprise the loss of lysine residues. In the case of a-
enolase from SV18 and SV41, substitution of K
251 or K
254,
respectively, was associated with a moderately increased affinity
for plasminogen. However, there were no compensating mutations
that lead to lysine residues at other sites of the protein from SV18
(Fig. 4A). The result challenges the critical role of the IPM lysine
K
251. Only one additional lysine (K
229) was observed in the
Table 1. Internal plasminogen binding motif (IPM) of a-enolase of oral streptococci.
Group (Sub-)Species No. of Isolates Strains IPM
Anginosus group S. anginosus 8 SV29, SV33, SV38, SV52, SV66, SV75, SV91, SV92 FYDKERKVY
S. constellatus ssp. constellatus 5 SV21, SV94, SV95, SV97, SV99 FYDKERKVY
S. constellatus ssp. pharyngis 2 SV35, SV102 FYDKERKVY
S. intermedius 4 SV101, SV103, SV105, SV106 FYDKERKVY
Mitis group S. gordonii 2 SV55, SV118 FYDKERKVY
S. mitis 1S V 2 8 FYDKERQVY
5 SV111, SV112, SV113, SV114, SV115 FYDKERKVY
S. oralis 1S V 1 8 FYDKERQVY
6 SV11, SV12, SV51, SV54, SV116, SV117 FYDKERKVY
S. parasanguinis 6 SV13, SV50, SV126 SV127, SV132, SV134 FYDKERKVY
S. sanguinis 7 SV20, SV73, SV119, SV121, SV122, SV123, SV125 FYDKERKVY
Salivarius group S. salivarius 2 SV17, SV107 FYENG—VY
1S V 3 2 FYDKERKVY
6 SV37, SV41, SV69, SV87, SV89, SV109 FYDAERKVY
doi:10.1371/journal.pone.0013826.t001
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remains to be tested. On the contrary, in the plasminogen binding
a-enolases of SV17 and SV90, the loss of both lysine residues was
accompanied by an increase in the number of lysine residues in the
vicinity of the IPM (Fig. 4B), suggesting compensatory mutations
and a lysine dependent mode of binding. Interestingly, strains with
such a-enolases (SV17 and SV107) displayed faster plasminogen
activation in assays with whole bacteria (Fig. 6). These consider-
ations shed only limited light on the nature of the plasminogen
binding, which may differ between a-enolase variants and should
be resolved by structural biology techniques. However, it is
possible to summarize that the ability to bind plasmin(ogen)
remains conserved in oral streptococci in spite of variations in the
IPM. The observed functional conservation points towards a
critical role of this interaction in pathogenic as well as commensal
streptococci. A previous study suggested that the surface bound
Figure 4. Alignment of recombinant a-enolase variants. Proteins sequences of recombinant a-enolases originating from oral streptococcal
strains (A) SV11, SV18, SV41 and from (B) SV11, SV17, SV90 were aligned using CLUSTALW 2.0.12. Streptococcal species and strain designation are
indicated at the left, followed by the apparent dissociation constant for plasminogen interaction in brackets (see also: Fig. 5). Dots indicate amino
acids that are identical in the upper sequence. Substitutions by lysine are highlighted in gray. The IPM and its variants are depicted in bold.
doi:10.1371/journal.pone.0013826.g004
Figure 5. Interaction between human plasminogen and recombinant a-enolase variants. Binding was analyzed in a ligand blot
experiment (A) with immobilized recombinant a-enolase variants (5 mg and 1 mg) and human plasminogen as soluble analyte. Designation of the
original oral streptococcal strain and the IPM are given together with the apparent dissociation constants, which where determined by surface
plasmon resonance measurements (B–F) at different analyte concentrations (4 mM, 2 mM and 1 mM a-enolase). Although curve shapes suggested
interactions of higher complexity, apparent dissociation constants were determined based on the Langmuir model for 1:1 interaction.
doi:10.1371/journal.pone.0013826.g005
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since it facilitates adhesion to pharyngeal cells [37]. The cell
adhesion function may provide additional selection pressure that
has led to conservation of the plasminogen interaction in
a-enolase.
Plasminogen activation depends on a multifactorial interaction
with the bacterial surface. To gain a holistic view of it, we have
compared plasminogen activation by oral streptococci strains with
differences in the IPM of a-enolase. All strains studied generated
plasmin-activity in human plasma, indicating that the naturally
occurring differences in the IPM, in contrast to targeted
inactivating mutations [24], do not decrease plasminogen
activation. This may be due to either a conserved efficacy of the
IPM, emergence of alternative binding motifs or compensating
processes that comprise alternative plasminogen activating factors
as well as differences in protein expression, extracellular secretion,
and binding to the streptococcal surface.
In conclusion, activation of human plasminogen is common not
only to typical streptococcal pathogens like S. pneumoniae, but also
to oral streptococci. This may at least partially explain their
facultative pathogenic character, which is observed in several
niches of the human body.
Materials and Methods
Bacterial strains
Clinical isolates of oral streptococci were collected at the
University Hospital Leipzig, Germany and their species was
determined as described previously [38]. Bacterial strains were
grown on Columbia agar containing 5% sheep blood (Becton
Dickinson) or as liquid cultures inoculated from single colonies in
Todd-Hewitt broth (Becton Dickinson) that was supplemented
with 0.5% yeast extract (THY). The cultures were incubated at
37uC in an atmosphere with 5% CO2.
SDS-Polyacrylamide Gel Electrophoresis and
Immunoblots
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was
performed as described by Laemmli [39]. For immunoblots, the
proteins were electrophoretically transferred to nitrocellulose
membranes (BioRad). Unbound nitrocellulose was saturated by
incubation with blocking buffer (5% (w/v) skim milk in phosphate
buffered saline pH 7.0 (PBS)) for 1 h, before the membranes were
incubated with a dilution of the appropriate antiserum or antibody
solution in blocking buffer. If not directly conjugated to horse
radish peroxidase (HRP), bound antibodies were detected using
peroxidase-conjugated swine anti-rabbit IgG (Dakopats). Peroxi-
dase activity was detected by chemiluminescence using 100 mM
Tris HCl, 1.25 mM 3-aminopthalhydrazide, 225 mM p-coumaric
acid, 0.01% H2O2 at pH 8.8 in water and chemiluminescence
films (GE Healthcare).
Binding experiments with plasma proteins and whole
bacteria
Cells from 50 ml overnight liquid culture of S. oralis SV11 were
harvested by centrifugation for 10 min at 40006g, washed twice
with PBS and resuspended either in 1 ml sterile-filtered human
blood plasma, 1 ml PBS or in 1 ml PBS containing 180 ng/ml
purified human plasminogen (Sigma). After incubation for 1 h
with shaking (1000 rpm) at 37uC the cells were harvested by
centrifugation for 10 min at 160006g and washed twice with PBS
to remove unbound protein. Surface-bound proteins were eluted
either by incubating the cells in 100 ml 0.1 M glycine pH 2.0 for
10 min at room temperature (RT) or reducing SDS-Sample buffer
[39] for 5 min at 95uC. Bacterial cells were pelleted by
centrifugation for 10 min at 160006g and the supernatants
collected. Acidic supernatants were neutralized by adding 10 ml
1 M Tris-HCl pH 9.0. The samples were analysed by SDS-PAGE
Figure 6. Comparison of plasminogen activation in human blood plasma by oral streptococci. Bacterial cells from mid-logarithmic
culture of eight different oral streptococci strains with 4 different IPMs (Table 1) were incubated in human blood plasma (% and e). Plasma without
bacterial cells (#) served as a control. Plasminogen activation was measured using the colour reaction of plasmin-specific substrate (S-2251).
Absorbance of the liquid phase was measured over time at a wavelength of 405 nm. Bars represent the standard deviation of the experimental
triplicates.
doi:10.1371/journal.pone.0013826.g006
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detected in immunoblots using polyclonal affinity purified HRP-
coupled goat antibody directed against human IgG (Jackson
ImmunoResearch). Plasminogen was detected using polyclonal
rabbit anti-human plasminogen antibody (American Diagnostica)
in combination with HRP-coupled goat anti-rabbit IgG secondary
antibody.
Mass spectrometry
Protein bands were excised from the gel after SDS-PAGE,
processed for and analysed by Matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF-MS) as
described previously [40].
Alkaline eluates of bacterial surface bound proteins
Bacteria from 50 ml overnight culture of S. oralis SV11 were
washed twice in 0.1 M sodium acetate (pH 5.4). Surface bound
proteins were eluted by incubating the cells in 100 ml 0.1 M
sodium carbonate buffer (pH 10) for 30 min at 37uC. Bacterial
cells were pelleted by 10 min centrifugation at 160006g. The
supernatants were analyzed by 10% SDS-PAGE and immunoblots
with rabbit-raised antisera specific for streptococcal a-enolase [21]
or GAPDH [20], respectively.
Plasminogen activation by whole bacteria and by
recombinant a-enolase
Overnight cultures of the bacteria were diluted 1:30 in 50 ml
THY and grown until mid-logarithmic growth-phase
(OD600 nm=0.6). Bacteria were harvested by centrifugation for
10 min at 40006g and washed twice with PBS before they were
resuspended in 1 ml filtered (0.2 mm) human blood plasma or
PBS. When required, 100 ng urokinase (Sigma-Aldrich) was
added. Samples without bacteria were used as controls. To
monitor plasminogen activation, the plasmin-specific chromogenic
substrate S-2251 (Chromogenix) was added to a final concentra-
tion of 400 mM and the samples were incubated for 6.5 h while
shaking (1000 rpm) at 37uC. At 30 min time intervals, 100 ml
samples were taken and centrifuged for 5 min at 160006g before
the absorbance of the supernatant was measured at a wavelength
of 405 nm in an ELISA-reader (Tecan). Analogously, the
plasminogen activation by a-enolase was studied using the isolated
recombinant proteins (1 mg) instead of the bacteria.
Sequencing of the eno-gene
Genomic DNA was isolated from 15 ml overnight culture of
oral streptococci using the DNeasyH Blood & Tissue Kit (Qiagen)
with minor modification of the manufacturer’s protocol. Bacteria
were washed twice with PBS and lysed by incubation for 30 min at
37uC in 460 ml lysis-buffer (20 mM Tris-HCl, 2 mM EDTA, 1.2%
TritonX-100, pH 8) containing 250 U mutanolysin (Fluka) and
50 mg RNAse A (AppliChem). Polymerase chain reaction on the
streptococcal DNA with the primers Eno1 (GAC TCA CGC
GGT AAC CCA AC) and Eno2 (ATT GTT GAA TCT TCA
GTT TCA CC) produced 1.1 kb amplicons of internal coding
sequence. For sequencing of the 39-end the internal primer
EnoLys1 (CTC AAT CCT TAT CAA AGT TAA CC) was used
in combination with one of the external primers EnoLys2 (GGG
CTA GAA ACG TTG TTA AAT C), EnoLys4 (GCC AGT TCT
TCA ATC TTG TCC), Eno Lys6 (CTG GAT AAC GTT CAA
ACA TCG) or EnoLys7 (CCA ATG GAA TTA TTT AAC CAA
G). The PCR products were purified using the QIAquick PCR
Purification Kit (Qiagen) and sequenced using aforementioned
primers, the BigDyeH Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems) and an ABI Prism 377 system (Applied
Biosystems). Sequence data were processed and analysed using the
software BioEdit (version 7.0.8, Ibis Biosciences) and deposited in
the GenBank database (GenBank accession numbers: HM751882-
HM751937 and HQ389262-HQ389317).
Cloning, overexpression and purification of recombinant
a-enolase
The eno genes were amplified from chromosomal DNA using
forward and reverse primers incorporating a BamHI or SalI
restriction site, respectively (primer 1: GCG GAT CCA TGT
CAA TTA TTA CTG ATG TTT ACG, primer 2: GCT GTC
GAC TTA TTA TTT TTT AAG GTT GTA GAA TGA TTT).
Amplified eno genes were cloned into the multiple cloning site of
the pGEX-6P vector (GE Healthcare), according to manufactur-
er’s instructions, resulting in a fusion protein with an N-terminal
glutathione S-transferase (GST) tag. Recombinant a-enolase was
overexpressed and purified, according to manufacturer’s instruc-
tions, from 500 ml E. coli HB101 cultures, using Glutathione
Sepharose
TM 4 Fast Flow (GE Healthcare) affinity chromatogra-
phy. The recombinant a-enolase was cleaved from the GST-tag
and released from the glutathione-sepharose column by incubation
with 80 U of Precission protease per bed volume of glutathione-
sepharose (GE Healthcare) in PBS overnight at 4uC. Protein
eluates were dialysed against 2 l PBS overnight at 4uC. Purity of
the protein fractions was analysed by SDS-PAGE (12% gel) and
protein concentration was determined using bicinchoninic acid
(Sigma-Aldrich).
Surface plasmon resonance measurements
Protein interactions were studied by surface plasmon resonance
measurements in a BIAcore 2000 system (BIAcore AB) as
described earlier [40]. Human plasminogen (Sigma-Aldrich) was
dissolved in 10 mM sodium acetate, pH 5.0 at a concentration of
500 mg/ml. Injection of 20 ml at a flow rate of 5 ml/min led to
immobilization of 3500 response units (RU) of plasminogen.
Residual reactive groups were inactivated by a 7 min injection of
1 M ethanolamine, 0.1 M NaHCO3, 0.5 M NaCl, 5 mM EDTA,
pH 8.0. Surface regeneration was achieved by injection of two
30 s pulses of 0.2% SDS in water. Recombinant a-enolase as the
analyte was diluted in running buffer at concentrations of 4 mM,
2 mM and 1 mM. The interaction was measured at a flow rate of
60 ml/min. The BIAevaluation 3.0 software was used for further
analysis of the data. Shown curves represent the difference
between the signal of the collagen-coupled surface and of a
deactivated control surface devoid of protein. They were further
corrected by subtraction of the curve that was obtained after
injection of buffer alone. Buffer injection led to responses less than
5 RU.
Ligand blots
Recombinant a-enolase variants were dot-blotted onto nitro-
cellulose (5 mg and 1 mg) before blocking with 5% (w/v) skim milk
in PBS for 1 h at RT. The membrane was washed for 5 min in
PBS and probed with 50 mg human plasminogen (Sigma-Aldrich,
Germany) for 2 h. Then the membrane was washed 3 times for
5 min with PBS. Binding of plasminogen was detected with a
rabbit raised primary antibody directed against plasminogen
(Affinity Biologicals, 1:200 in blocking buffer), followed by an
HRP-conjugated secondary antibody incubation (DAKO, 1:3000
in blocking buffer), which after washing with PBS (3 times for
5 min) was detected using 1 mg/ml 4-chlor-1-naphthol and 0.1%
H2O2 in water.
Streptococci Activate Plasmin
PLoS ONE | www.plosone.org 9 November 2010 | Volume 5 | Issue 11 | e13826Acknowledgments
We thank Katja Mummenbrauer for excellent technical assistance.
Author Contributions
Conceived and designed the experiments: AI CMG ACR DPNS.
Performed the experiments: AI CMG MF CF DPNS. Analyzed the data:
AI CMG MF CF GSC DPNS. Contributed reagents/materials/analysis
tools: CF ACR. Wrote the paper: CMG GSC DPNS.
References
1. Claridge JE, 3rd, Attorri S, Musher DM, Hebert J, Dunbar S (2001)
Streptococcus intermedius, Streptococcus constellatus, and Streptococcus
anginosus (‘‘Streptococcus milleri group’’) are of different clinical importance
and are not equally associated with abscess. Clin Infect Dis 32: 1511–1515.
2. Jacobs JA, Pietersen HG, Stobberingh EE, Soeters PB (1994) Bacteremia
involving the ‘‘Streptococcus milleri’’ group: analysis of 19 cases. Clin Infect Dis
19: 704–713.
3. Whiley RA, Beighton D, Winstanley TG, Fraser HY, Hardie JM (1992)
Streptococcus intermedius, Streptococcus constellatus, and Streptococcus
anginosus (the Streptococcus milleri group): association with different body sites
and clinical infections. J Clin Microbiol 30: 243–244.
4. Ruoff KL (1988) Streptococcus anginosus (‘‘Streptococcus milleri’’): the
unrecognized pathogen. Clin Microbiol Rev 1: 102–108.
5. Colombo AP, Haffajee AD, Dewhirst FE, Paster BJ, Smith CM, et al. (1998)
Clinical and microbiological features of refractory periodontitis subjects. J Clin
Periodontol 25: 169–180.
6. Douglas CW, Heath J, Hampton KK, Preston FE (1993) Identity of viridans
streptococci isolated from cases of infective endocarditis. J Med Microbiol 39:
179–182.
7. Westling K, Julander I, Ljungman P, Vondracek M, Wretlind B, et al. (2008)
Identification of species of viridans group streptococci in clinical blood culture
isolates by sequence analysis of the RNase P RNA gene, rnpB. J Infect 56:
204–210.
8. La ¨hteenma ¨ki K, Kuusela P, Korhonen TK (2001) Bacterial plasminogen
activators and receptors. FEMS Microbiol Rev 25: 531–552.
9. Berge A, Sjo ¨bring U (1993) PAM, a novel plasminogen-binding protein from
Streptococcus pyogenes. J Biol Chem 268: 25417–25424.
10. Kuusela P, Ullberg M, Saksela O, Kronvall G (1992) Tissue-type plasminogen
activator-mediated activation of plasminogen on the surface of group A, C, and
G streptococci. Infect Immun 60: 196–201.
11. Khil J, Im M, Heath A, Ringdahl U, Mundada L, et al. (2003) Plasminogen
enhances virulence of group A streptococci by streptokinase-dependent and
streptokinase-independent mechanisms. J Infect Dis 188: 497–505.
12. Coleman JL, Benach JL (1999) Use of the plasminogen activation system by
microorganisms. J Lab Clin Med 134: 567–576.
13. Lottenberg R, Minning-Wenz D, Boyle MD (1994) Capturing host plasmin
(ogen): a common mechanism for invasive pathogens? Trends Microbiol 2:
20–24.
14. Sanderson-Smith ML, Dowton M, Ranson M, Walker MJ (2007) The
plasminogen-binding group A streptococcal M protein-related protein Prp
binds plasminogen via arginine and histidine residues. J Bacteriol 189:
1435–1440.
15. Ben Nasr A, Wistedt A, Ringdahl U, Sjobring U (1994) Streptokinase activates
plasminogen bound to human group C and G streptococci through M-like
proteins. Eur J Biochem 222: 267–276.
16. Sanderson-Smith ML, Dinkla K, Cole JN, Cork AJ, Maamary PG, et al. (2008)
M protein-mediated plasminogen binding is essential for the virulence of an
invasive Streptococcus pyogenes isolate. Faseb J 22: 2715–2722.
17. Pancholi V, Fischetti VA (1998) alpha-enolase, a novel strong plasmin(ogen)
binding protein on the surface of pathogenic streptococci. J Biol Chem 273:
14503–14515.
18. Pancholi V, Fischetti VA (1993) Glyceraldehyde-3-phosphate dehydrogenase on
the surface of group A streptococci is also an ADP-ribosylating enzyme. Proc
Natl Acad Sci U S A 90: 8154–8158.
19. Pancholi V, Chhatwal GS (2003) Housekeeping enzymes as virulence factors for
pathogens. Int J Med Microbiol 293: 391–401.
20. Bergmann S, Rohde M, Hammerschmidt S (2004) Glyceraldehyde-3-phosphate
dehydrogenase of Streptococcus pneumoniae is a surface-displayed plasmino-
gen-binding protein. Infect Immun 72: 2416–2419.
21. Bergmann S, Rohde M, Chhatwal GS, Hammerschmidt S (2001) alpha-Enolase
of Streptococcus pneumoniae is a plasmin(ogen)-binding protein displayed on
the bacterial cell surface. Mol Microbiol 40: 1273–1287.
22. Bergmann S, Rohde M, Preissner KT, Hammerschmidt S (2005) The nine
residue plasminogen-binding motif of the pneumococcal enolase is the major
cofactor of plasmin-mediated degradation of extracellular matrix, dissolution of
fibrin and transmigration. Thromb Haemost 94: 304–311.
23. Derbise A, Song YP, Parikh S, Fischetti VA, Pancholi V (2004) Role of the C-
terminal lysine residues of streptococcal surface enolase in Glu- and Lys-
plasminogen-binding activities of group A streptococci. Infect Immun 72:
94–105.
24. Bergmann S, Wild D, Diekmann O, Frank R, Bracht D, et al. (2003)
Identification of a novel plasmin(ogen)-binding motif in surface displayed alpha-
enolase of Streptococcus pneumoniae. Mol Microbiol 49: 411–423.
25. Jones MN, Holt RG (2007) Cloning and characterization of an alpha-enolase of
the oral pathogen Streptococcus mutans that binds human plasminogen.
Biochem Biophys Res Commun 364: 924–929.
26. Kawamura Y, Hou XG, Sultana F, Miura H, Ezaki T (1995) Determination of
16S rRNA sequences of Streptococcus mitis and Streptococcus gordonii and
phylogenetic relationships among members of the genus Streptococcus. Int J Syst
Bacteriol 45: 406–408.
27. Cork AJ, Jergic S, Hammerschmidt S, Kobe B, Pancholi V, et al. (2009)
Defining the structural basis of human plasminogen binding by streptococcal
surface enolase. J Biol Chem 284: 17129–17137.
28. Walker MJ, McArthur JD, McKay F, Ranson M (2005) Is plasminogen deployed
as a Streptococcus pyogenes virulence factor? Trends Microbiol 13: 308–313.
29. Sun H, Ringdahl U, Homeister JW, Fay WP, Engleberg NC, et al. (2004)
Plasminogen is a critical host pathogenicity factor for group A streptococcal
infection. Science 305: 1283–1286.
30. (1947) Studies on Streptococcal Fibrinolysis: V. The in Vitro Production of
Fibrinolysin by Various Groups and Types of Beta Hemolytic Streptococci;
Relationship to Antifibrinolysin Production. J Exp Med 85: 441–457.
31. Christensen LR (1945) Streptococcal Fibrinolysis: A Proteolytic Reaction Due to
a Serum Enzyme Activated by Streptococcal Fibrinolysin. J Gen Physiol 28:
363–383.
32. Antikainen J, Kuparinen V, Lahteenmaki K, Korhonen TK (2007) Enolases
from Gram-positive bacterial pathogens and commensal lactobacilli share
functional similarity in virulence-associated traits. FEMS Immunol Med
Microbiol 51: 526–534.
33. Mangel WF, Lin BH, Ramakrishnan V (1990) Characterization of an extremely
large, ligand-induced conformational change in plasminogen. Science 248:
69–73.
34. Ramakrishnan V, Patthy L, Mangel WF (1991) Conformation of Lys-
plasminogen and the kringle 1-3 fragment of plasminogen analyzed by small-
angle neutron scattering. Biochemistry 30: 3963–3969.
35. Marshall JM, Brown AJ, Ponting CP (1994) Conformational studies of human
plasminogen and plasminogen fragments: evidence for a novel third conforma-
tion of plasminogen. Biochemistry 33: 3599–3606.
36. Markus G, DePasquale JL, Wissler FC (1978) Quantitative determination of the
binding of epsilon-aminocaproic acid to native plasminogen. J Biol Chem 253:
727–732.
37. Pancholi V, Fontan P, Jin H (2003) Plasminogen-mediated group A
streptococcal adherence to and pericellular invasion of human pharyngeal cells.
Microb Pathog 35: 293–303.
38. Friedrichs C, Rodloff AC, Chhatwal GS, Schellenberger W, Eschrich K (2007)
Rapid identification of viridans streptococci by mass spectrometric discrimina-
tion. J Clin Microbiol 45: 2392–2397.
39. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature 227: 680–685.
40. Nitsche DP, Johansson HM, Frick IM, Mo ¨rgelin M (2006) Streptococcal protein
FOG, a novel matrix adhesin interacting with collagen I in vivo. J Biol Chem
281: 1670–1679.
Streptococci Activate Plasmin
PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e13826